| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 31st December 2020 | Richard C Jr Pfenniger | 3,125 | Grant/award etc. | $0.00 | |
| 31st December 2020 | Richard C Jr Pfenniger | 2,800 | Grant/award etc. | $0.00 | |
| 30th September 2020 | Richard C Jr Pfenniger | 2,198 | Grant/award etc. | $0.00 | |
| 30th September 2020 | David Bruce Milne | 14,750 | Grant/award etc. | $0.00 | |
| 30th September 2020 | Richard C Jr Pfenniger | 16,500 | Grant/award etc. | $0.00 | |
| 30th September 2020 | Richard C Jr Pfenniger | 3,125 | Grant/award etc. | $0.00 | |
| 3rd July 2020 | Anthony C. J. Fernando | 17,949 | Exercise of derivative | $0.00 | |
| 30th June 2020 | Brett Farabaugh | 30,000 | Exercise of derivative | $0.00 | |
| 30th June 2020 | Richard C Jr Pfenniger | 2,403 | Grant/award etc. | $0.00 | |
| 30th June 2020 | Richard C Jr Pfenniger | 3,125 | Grant/award etc. | $0.00 |
Trans Enterix
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 3/10.
TransEnterix, Inc. is a medical device company. It focuses on commercialization of Senhance System, that digitizes laparoscopic minimally invasive surgery. The company was founded by William N. Starling in 2006.
Ticker: TRXC
Sector: Commercial Services
Industry: Miscellaneous Commercial Services
SEC Central Index Key (CIK): 876378
Employees: 163
Exchange: NYSE American
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
Restructuring Charges of $900 Th for the period Jan 2020 to Jun 2020 in the context of Employee severance
Restructuring Charges of $858 Th for the period Jan 2020 to Jun 2020 in the context of all up
Restructuring Charges of $9 M for the period Oct 2019 to Dec 2019 in the context of all up
Restructuring Charges of $7 M for the period Oct 2019 to Dec 2019 in the context of Cost of sales
Restructuring Charges of $1 M for the period Oct 2019 to Dec 2019 in the context of Restructuring and other charges
Goodwill Impairment Loss of $79 M for the period Oct 2019 to Dec 2019 in the context of all up
Fundamentals
Cash at Carrying Value: $16 M (0%)
Inventory, Net: $11 M (0%)
Other Assets, Current: $7 M (-2%)
Assets, Current: $34 M (22%)
Property, Plant and Equipment, Net: $7 M (47%)
Other Assets, Noncurrent: $2 M (-23%)
Assets: $76 M (1%)
Accounts Payable, Current: $2 M (-34%)
Accrued Liabilities, Current: $7 M (-20%)
Liabilities, Current: $10 M (-22%)
Other Liabilities, Noncurrent: $1 M (-22%)
Liabilities: $16 M (-14%)
Common Stock, Value, Issued: $57 Th (171%)
Common Stock, Shares, Issued: $57 M (175%)
Additional Paid in Capital, Common Stock: $755 M (4%)
Retained Earnings (Accumulated Deficit): $694 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $1 M (-6%)
Stockholders' Equity (Parent): $60 M (0%)
Liabilities and Equity: $76 M (1%)
Revenue: $655 Th (0%)
Cost of Revenue: $1 M (-55%)
Gross Margin: $758 Th (-60%)
Research and Development: $4 M (-48%)
Sales and Marketing: $3 M (-59%)
General and Administrative Expenses: $4 M (-48%)
Restructuring Charges: $858 Th (-90%)
Operating Income/Loss: $14 M (-54%)
Other Income, net: $165 Th (-46%)
Provision for income taxes: $691 Th (-50%)
EPS (basic): $0.27 (-64%)
EPS (diluted): $0.27 (-64%)
News
DXP Enterprises Reports Third Quarter 2020 Results
6th November 2020
17 Arrested For Running Fake Call Centre In Delhi: Police
6th November 2020
Ubiquiti Inc. Reports First Quarter Fiscal 2021 Financial Results
6th November 2020
